Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Digene Rapid Capture

This article was originally published in The Gray Sheet

Executive Summary

High-volume sample throughput instrument gains PMA supplement approval for use with the firm's HC2 HPV DNA test, also marketed as DNAwithPap for primary human papillomavirus screening in conjunction with Pap smear. The system incorporates automated pipetting and microplate processing to analyze 352 patient samples in a 6.5-hour lab shift, and is expected to facilitate DNAwithPap adoption by large labs, Digene says (1"The Gray Sheet" Nov. 10, 2003, In Brief). Rapid Capture previously was cleared for use with Digene chlamydia and gonorrhea tests. HPV sales drove Digene revenue up 39% to $23.6 mil. for its fiscal third quarter (ended March 31)...

You may also be interested in...



Digene Rapid Capture

PMA supplement for high-volume sample throughput instrument is submitted to FDA for use with the firm's DNAwithPap HPV test. The system incorporates automated pipetting and microplate processing to analyze over 350 patient samples in an eight-hour lab shift, Digene claims...

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Health And Wellness Weekly Trademarks Review: 16 April

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT020187

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel